300485 赛升药业
已收盘 02-04 15:00:00
资讯
新帖
简况
股市必读：赛升药业（300485）预计2025年全年扣非后净利润亏损2347.07万元至2868.64万元
证券之星 · 02-02 03:06
股市必读：赛升药业（300485）预计2025年全年扣非后净利润亏损2347.07万元至2868.64万元
赛升药业（300485）披露2025年度业绩预告，1月30日股价下跌0.9%
证券之星 · 01-30
赛升药业（300485）披露2025年度业绩预告，1月30日股价下跌0.9%
赛升药业(300485)1月20日股东户数3.41万户，较上期减少0.04%
证券之星 · 01-26
赛升药业(300485)1月20日股东户数3.41万户，较上期减少0.04%
赛升药业：公司控股子公司拥有治疗流感类产品
证券之星 · 01-26
赛升药业：公司控股子公司拥有治疗流感类产品
赛升药业控股股东一致行动人马丽减持计划期满，累计减持1.33%股份
中金财经 · 01-20
赛升药业控股股东一致行动人马丽减持计划期满，累计减持1.33%股份
赛升药业2025年度审计机构项目合伙人变更，由刘均山变更为闫磊
中金财经 · 01-20
赛升药业2025年度审计机构项目合伙人变更，由刘均山变更为闫磊
赛升药业子公司赛而生物通过高新技术企业重新认定
中金财经 · 01-20
赛升药业子公司赛而生物通过高新技术企业重新认定
股市必读：1月19日赛升药业现1笔折价12.13%的大宗交易 合计成交780万元
证券之星 · 01-20
股市必读：1月19日赛升药业现1笔折价12.13%的大宗交易 合计成交780万元
赛升药业：1月14日高管马丽减持股份合计230.18万股
证券之星 · 01-15
赛升药业：1月14日高管马丽减持股份合计230.18万股
赛升药业：形成五大战略平台集团化发展布局
证券之星 · 01-15
赛升药业：形成五大战略平台集团化发展布局
赛升药业：1月13日高管马丽减持股份合计326.52万股
证券之星 · 01-14
赛升药业：1月13日高管马丽减持股份合计326.52万股
1月13日赛升药业现1笔折价12.01%的大宗交易 合计成交877.4万元
证券之星 · 01-13
1月13日赛升药业现1笔折价12.01%的大宗交易 合计成交877.4万元
股市必读：赛升药业(300485)股东户数3.36万户，较上期减少2.16%
证券之星 · 01-09
股市必读：赛升药业(300485)股东户数3.36万户，较上期减少2.16%
赛升药业（300485）披露向子公司君元药业提供财务资助展期，12月29日股价下跌0.28%
证券之星 · 2025-12-29
赛升药业（300485）披露向子公司君元药业提供财务资助展期，12月29日股价下跌0.28%
赛升药业：截至2025年12月19日股东户数为34363
证券之星 · 2025-12-24
赛升药业：截至2025年12月19日股东户数为34363
赛升药业：截至2025年12月10日股东户数为35036
证券之星 · 2025-12-15
赛升药业：截至2025年12月10日股东户数为35036
赛升药业（300485）披露子公司收到药品注册上市许可申请受理通知书，12月4日股价下跌0.17%
证券之星 · 2025-12-04
赛升药业（300485）披露子公司收到药品注册上市许可申请受理通知书，12月4日股价下跌0.17%
赛升药业(300485.SZ)：达格列净二甲双胍缓释片药品注册上市许可申请获受理
智通财经 · 2025-12-04
赛升药业(300485.SZ)：达格列净二甲双胍缓释片药品注册上市许可申请获受理
赛升药业：11月18日高管马丽减持股份合计6.3万股
证券之星 · 2025-11-19
赛升药业：11月18日高管马丽减持股份合计6.3万股
股市必读：赛升药业(300485)股东户数3.56万户，较上期减少4.03%
证券之星 · 2025-11-18
股市必读：赛升药业(300485)股东户数3.56万户，较上期减少4.03%
加载更多
公司概况
公司名称：
北京赛升药业股份有限公司
所属行业：
医药制造业
上市日期：
2015-06-26
主营业务：
北京赛升药业股份有限公司的主营业务是注射针剂的研发、生产及销售。公司的主要产品是免疫系统用药、神经系统用药、心脑血管用药。赛盈纤溶酶注射液被评选为2023年年度生化生物企业优秀品牌，赛典单唾液酸四己糖神经节苷脂钠注射液被评为2024年度生化、生物药品优秀品牌。
发行价格：
38.46
{"stockData":{"symbol":"300485","market":"SZ","secType":"STK","nameCN":"赛升药业","latestPrice":11.07,"timestamp":1770188601000,"preClose":11.04,"halted":0,"volume":4493900,"delay":0,"changeRate":0.0027,"floatShares":274000000,"shares":482000000,"eps":0.1686,"marketStatus":"已收盘","change":0.03,"latestTime":"02-04 15:00:00","open":11.01,"high":11.08,"low":10.91,"amount":49478300,"amplitude":0.0154,"askPrice":11.07,"askSize":20,"bidPrice":11.06,"bidSize":627,"shortable":0,"etf":0,"ttmEps":0.1686,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770255000000},"marketStatusCode":5,"adr":0,"adjPreClose":11.04,"symbolType":"stock","openAndCloseTimeList":[[1770168600000,1770175800000],[1770181200000,1770188400000]],"highLimit":12.14,"lowLimit":9.94,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":481666400,"isCdr":false,"pbRate":1.56,"roa":"--","peRate":65.658363,"roe":"1.53%","epsLYR":-0.14,"committee":0.549104,"marketValue":5332000000,"turnoverRate":0.0164,"status":0,"floatMarketCap":3031000000},"requestUrl":"/m/hq/s/300485","defaultTab":"news","newsList":[{"id":"2608889874","title":"股市必读：赛升药业（300485）预计2025年全年扣非后净利润亏损2347.07万元至2868.64万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608889874","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608889874?lang=zh_cn&edition=full","pubTime":"2026-02-02 03:06","pubTimestamp":1769972775,"startTime":"0","endTime":"0","summary":"来自：赛升药业预计2025年扣非后净利润亏损2347.07万元至2868.64万元，同比大幅下降。交易信息汇总1月30日主力资金净流出877.85万元；游资资金净流入115.1万元；散户资金净流入762.75万元。赛升药业发布业绩预告，预计2025年全年归属净利润盈利1377.37万元至2000万元。公司公告汇总北京赛升药业股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润为1,377.37万元至2,000万元，实现扭亏为盈。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200001463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485"],"gpt_icon":0},{"id":"2607044612","title":"赛升药业（300485）披露2025年度业绩预告，1月30日股价下跌0.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607044612","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607044612?lang=zh_cn&edition=full","pubTime":"2026-01-30 22:54","pubTimestamp":1769784855,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，赛升药业报收于11.05元，较前一交易日下跌0.9%，最新总市值为53.22亿元。该股当日开盘11.15元，最高11.38元，最低10.98元，成交额达7588.03万元，换手率为2.49%。北京赛升药业股份有限公司于2026年1月30日披露《2025年度业绩预告》。公告显示，公司预计2025年度归属于上市公司股东的净利润为1,377.37万元至2,000万元，实现扭亏为盈。非经常性损益对净利润影响约为4,300万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000047756.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300485","BK0046","BK0012"],"gpt_icon":0},{"id":"2606219588","title":"赛升药业(300485)1月20日股东户数3.41万户，较上期减少0.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606219588","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606219588?lang=zh_cn&edition=full","pubTime":"2026-01-26 18:22","pubTimestamp":1769422979,"startTime":"0","endTime":"0","summary":"证券之星消息，近日赛升药业披露，截至2026年1月20日公司股东户数为3.41万户，较1月10日减少12.0户，减幅为0.04%。在生物制品行业个股中，赛升药业股东户数低于行业平均水平，截至1月20日，生物制品行业平均股东户数为3.44万户。从股价来看，2026年1月10日至2026年1月20日，赛升药业区间跌幅为0.52%，在此期间股东户数减少12.0户，减幅为0.04%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600025068.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0012","BK0028","300485","BK0239"],"gpt_icon":0},{"id":"2606180294","title":"赛升药业：公司控股子公司拥有治疗流感类产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2606180294","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606180294?lang=zh_cn&edition=full","pubTime":"2026-01-26 15:04","pubTimestamp":1769411069,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)01月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，央广网提醒，16号到20号罕见的流感病毒，是否对贵公司的业绩有影响赛升药业回复：您好，公司控股子公司拥有治疗流感类产品，药品使用须遵医嘱。流感类产品占主营业务收入较少，请投资者注意投资风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600014178.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","BK0012","300485","BK0239"],"gpt_icon":0},{"id":"2604116316","title":"赛升药业控股股东一致行动人马丽减持计划期满，累计减持1.33%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2604116316","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604116316?lang=zh_cn&edition=full","pubTime":"2026-01-20 21:31","pubTimestamp":1768915872,"startTime":"0","endTime":"0","summary":"中访网数据 北京赛升药业股份有限公司近日公告，公司控股股东、实际控制人马骉的一致行动人马丽女士的股份减持计划期限已届满。根据公告，在2025年11月18日至2026年1月19日期间，马丽女士通过集中竞价和大宗交易方式，合计减持公司股份641万股，占公司总股本的1.33%，减持总金额约人民币7,254万元。此次减持后，马丽女士持股比例由6.20%降至4.87%。另一致行动人刘淑芹女士在本次计划期内未进行减持。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260120/31957838.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0028","BK0239","300485","BK0012","BK0046"],"gpt_icon":0},{"id":"2604198059","title":"赛升药业2025年度审计机构项目合伙人变更，由刘均山变更为闫磊","url":"https://stock-news.laohu8.com/highlight/detail?id=2604198059","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604198059?lang=zh_cn&edition=full","pubTime":"2026-01-20 16:26","pubTimestamp":1768897589,"startTime":"0","endTime":"0","summary":"中访网数据 北京赛升药业股份有限公司(证券代码：300485)于1月20日发布公告，其2025年度审计机构致同会计师事务所(特殊普通合伙)发生项目合伙人变更。原指派的项目合伙人刘均山因内部工作调整，变更为闫磊。公告显示，新任项目合伙人闫磊自2004年起成为注册会计师并从事上市公司审计，具备相关执业经验。致同所表示，此次变更已安排有序交接，原定签字注册会计师及现场负责人保持不变，预计不会对公司2025年度财务报表及内部控制审计工作产生影响。公司此前已于2025年3月及4月通过董事会和股东大会决议，续聘致同所为2025年度审计机构。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260120/31956788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0046","BK0012","BK0028","300485","BK0239"],"gpt_icon":0},{"id":"2604198053","title":"赛升药业子公司赛而生物通过高新技术企业重新认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2604198053","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604198053?lang=zh_cn&edition=full","pubTime":"2026-01-20 16:26","pubTimestamp":1768897588,"startTime":"0","endTime":"0","summary":"中访网数据 北京赛升药业股份有限公司于1月20日发布公告，其全资子公司北京赛而生物药业有限公司已成功通过高新技术企业资格重新认定，并获得由北京市相关部门联合颁发的高新技术企业证书，证书编号GR202511004935，发证日期为2025年12月2日，有效期三年。此次认定为原证书到期后的复审通过。赛升药业主营业务为药品的研发、生产及销售，此次子公司资质延续体现了其在生物医药领域的持续创新能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260120/31956787.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0012","300485","BK0028","BK0239","BK0046"],"gpt_icon":0},{"id":"2604588261","title":"股市必读：1月19日赛升药业现1笔折价12.13%的大宗交易 合计成交780万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2604588261","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604588261?lang=zh_cn&edition=full","pubTime":"2026-01-20 02:39","pubTimestamp":1768847948,"startTime":"0","endTime":"0","summary":"截至2026年1月19日收盘，赛升药业报收于11.38元，上涨0.8%，换手率2.26%，成交量6.18万手，成交额6987.07万元。交易信息汇总资金流向1月19日主力资金净流入286.16万元；游资资金净流入537.4万元；散户资金净流出823.55万元。大宗交易1月19日赛升药业现1笔折价12.13%的大宗交易，合计成交780万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000001002.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300485","BK0012","BK0046","BK0239"],"gpt_icon":0},{"id":"2603600922","title":"赛升药业：1月14日高管马丽减持股份合计230.18万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2603600922","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603600922?lang=zh_cn&edition=full","pubTime":"2026-01-15 21:02","pubTimestamp":1768482150,"startTime":"0","endTime":"0","summary":"证券之星消息，根据1月15日市场公开信息、上市公司公告及交易所披露数据整理，赛升药业（300485）最新董监高及相关人员股份变动情况：2026年1月14日公司董事,高管马丽共减持公司股份230.18万股，占公司总股本为0.4779%。变动期间公司股价下跌2.47%，1月14日当日收盘报11.86元。赛升药业近半年内的董监高及核心技术人员增减持详情如下：赛升药业的高管列表及最新持股情况如下：该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500039264.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300485","BK0046","BK0028","BK0012"],"gpt_icon":0},{"id":"2603667916","title":"赛升药业：形成五大战略平台集团化发展布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2603667916","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603667916?lang=zh_cn&edition=full","pubTime":"2026-01-15 15:04","pubTimestamp":1768460654,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业01月15日在投资者关系平台上答复投资者关心的问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500019253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485","BK0239","BK0028","BK0046","BK0012"],"gpt_icon":0},{"id":"2603616436","title":"赛升药业：1月13日高管马丽减持股份合计326.52万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2603616436","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603616436?lang=zh_cn&edition=full","pubTime":"2026-01-14 21:02","pubTimestamp":1768395734,"startTime":"0","endTime":"0","summary":"证券之星消息，根据1月14日市场公开信息、上市公司公告及交易所披露数据整理，赛升药业（300485）最新董监高及相关人员股份变动情况：2026年1月13日公司董事,高管马丽共减持公司股份326.52万股，占公司总股本为0.6779%。变动期间公司股价上涨6.39%，1月13日当日收盘报12.16元。赛升药业近半年内的董监高及核心技术人员增减持详情如下：赛升药业的高管列表及最新持股情况如下：该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400039598.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0012","BK0028","300485","BK0239"],"gpt_icon":0},{"id":"2603502378","title":"1月13日赛升药业现1笔折价12.01%的大宗交易 合计成交877.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603502378","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603502378?lang=zh_cn&edition=full","pubTime":"2026-01-13 17:33","pubTimestamp":1768296797,"startTime":"0","endTime":"0","summary":"证券之星消息，1月13日赛升药业发生大宗交易，交易数据如下：大宗交易成交价格10.7元，相对当日收盘价折价12.01%，成交82万股，成交金额877.4万元，买方营业部为中国银河证券股份有限公司北京建国路证券营业部，卖方营业部为兴业证券股份有限公司上海自由贸易试验区分公司。近三个月该股共发生1笔大宗交易，合计成交8200.0手，折价成交1笔。截至2026年1月13日收盘，赛升药业报收于12.16元，上涨6.39%，换手率12.32%，成交量33.72万手，成交额4.1亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300029380.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0028","BK0012","300485","BK0239"],"gpt_icon":0},{"id":"2602394550","title":"股市必读：赛升药业(300485)股东户数3.36万户，较上期减少2.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602394550","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602394550?lang=zh_cn&edition=full","pubTime":"2026-01-09 01:55","pubTimestamp":1767894913,"startTime":"0","endTime":"0","summary":"截至2026年1月8日收盘，赛升药业报收于11.25元，上涨1.26%，换手率2.79%，成交量7.65万手，成交额8634.3万元。来自股本股东变化：截至2025年12月31日股东户数环比下降2.16%，户均持股上升至1.43万股，筹码集中度有所提高。股本股东变化股东户数变动近日赛升药业披露，截至2025年12月31日公司股东户数为3.36万户，较12月19日减少742.0户，减幅为2.16%。户均持股数量由上期的1.4万股增加至1.43万股，户均持股市值为15.16万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900001189.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","BK0046","BK0028","300485"],"gpt_icon":0},{"id":"2595736431","title":"赛升药业（300485）披露向子公司君元药业提供财务资助展期，12月29日股价下跌0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595736431","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595736431?lang=zh_cn&edition=full","pubTime":"2025-12-29 22:56","pubTimestamp":1767020179,"startTime":"0","endTime":"0","summary":"截至2025年12月29日收盘，赛升药业报收于10.7元，较前一交易日下跌0.28%，最新总市值为51.54亿元。近日，赛升药业发布公告称，公司拟对子公司沈阳君元药业有限公司提供的不超过3,000万元财务资助进行展期，借款期限延长至2028年12月28日，年利率3%。君元药业为公司控股子公司，公司能有效控制其业务与资金管理，风险可控。截至公告日，公司对外提供财务资助总额为5,000万元，无逾期情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900038439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","300485","BK0046","BK0239","BK0028"],"gpt_icon":0},{"id":"2593442513","title":"赛升药业：截至2025年12月19日股东户数为34363","url":"https://stock-news.laohu8.com/highlight/detail?id=2593442513","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593442513?lang=zh_cn&edition=full","pubTime":"2025-12-24 09:06","pubTimestamp":1766538371,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)12月23日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，您好！请问公司截至12月20日公司的股东人数是多少？谢谢赛升药业回复：您好，截至2025年12月19日，公司股东户数为34363。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400006460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485","BK0028","BK0012","BK0239","BK0046"],"gpt_icon":0},{"id":"2591661157","title":"赛升药业：截至2025年12月10日股东户数为35036","url":"https://stock-news.laohu8.com/highlight/detail?id=2591661157","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591661157?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:45","pubTimestamp":1765788350,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)12月15日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，截止到2025年12月12日公司最近的股东户数是多少，谢谢赛升药业回复：您好，截至2025年12月10日，公司股东户数为35036。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500019024.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","300485","BK0046","BK0239","BK0028"],"gpt_icon":0},{"id":"2588880978","title":"赛升药业（300485）披露子公司收到药品注册上市许可申请受理通知书，12月4日股价下跌0.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588880978","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588880978?lang=zh_cn&edition=full","pubTime":"2025-12-04 22:14","pubTimestamp":1764857665,"startTime":"0","endTime":"0","summary":"截至2025年12月4日收盘，赛升药业报收于11.45元，较前一交易日下跌0.17%，最新总市值为55.15亿元。该股当日开盘11.5元，最高11.56元，最低11.28元，成交额达6186.47万元，换手率为1.98%。公司近日发布公告称，其子公司北京赛而生物药业有限公司收到国家药品监督管理局下发的达格列净二甲双胍缓释片境内生产药品注册上市许可申请的《受理通知书》。药品注册批准时间及结果存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400039534.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300485","BK0012","BK0028","BK0046"],"gpt_icon":0},{"id":"2588011380","title":"赛升药业(300485.SZ)：达格列净二甲双胍缓释片药品注册上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2588011380","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588011380?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:02","pubTimestamp":1764835358,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛升药业(300485.SZ)发布公告，公司子公司北京赛而生物药业有限公司(以下简称“赛而生物”)近日收到了国家药品监督管理局下发的达格列净二甲双胍缓释片境内生产药品注册上市许可申请的《受理通知书》。SGLT-2抑制药达格列净和盐酸二甲双胍的复方片剂由英国阿斯利康制药公司研发，于2014年FDA批准上市。2023年6月，该品种在我国批准上市。SGLT-2 抑制剂是通过非胰岛素依赖机制发挥作用，通过减少葡萄糖在肾脏的重吸，从尿中直接排糖来降低血糖，SGLT-2联用二甲双胍表现了更好的降糖效果和更低的副作用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377662.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"赛升药业(300485.SZ)：达格列净二甲双胍缓释片药品注册上市许可申请获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300485","BK0239","BK0028","BK0046","BK0012"],"gpt_icon":0},{"id":"2584099949","title":"赛升药业：11月18日高管马丽减持股份合计6.3万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2584099949","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584099949?lang=zh_cn&edition=full","pubTime":"2025-11-19 21:02","pubTimestamp":1763557346,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月19日市场公开信息、上市公司公告及交易所披露数据整理，赛升药业（300485）最新董监高及相关人员股份变动情况：2025年11月18日公司董事,高管马丽共减持公司股份6.3万股，占公司总股本为0.0131%。变动期间公司股价下跌2.94%，11月18日当日收盘报12.86元。赛升药业近半年内的董监高及核心技术人员增减持详情如下：赛升药业的高管列表及最新持股情况如下：该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900037687.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","BK0012","BK0239","300485"],"gpt_icon":0},{"id":"2584678940","title":"股市必读：赛升药业(300485)股东户数3.56万户，较上期减少4.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584678940","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584678940?lang=zh_cn&edition=full","pubTime":"2025-11-18 01:06","pubTimestamp":1763399182,"startTime":"0","endTime":"0","summary":"截至2025年11月17日收盘，赛升药业报收于13.25元，下跌0.75%，换手率10.52%，成交量28.8万手，成交额3.8亿元。来自股本股东变化：截至11月10日股东户数环比下降4.03%，户均持股上升至1.35万股，筹码集中度提升。股本股东变化股东户数变动近日赛升药业披露，截至2025年11月10日公司股东户数为3.56万户，较10月20日减少1498.0户，减幅为4.03%。户均持股数量由上期的1.3万股增加至1.35万股，户均持股市值为16.53万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800000708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","BK0012","300485","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770231904476,"stockEarnings":[{"period":"1week","weight":-0.0323},{"period":"1month","weight":-0.009},{"period":"3month","weight":-0.0775},{"period":"6month","weight":-0.2485},{"period":"1year","weight":0.6279},{"period":"ytd","weight":0.0463}],"compareEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":0.0196},{"period":"3month","weight":0.0236},{"period":"6month","weight":0.1285},{"period":"1year","weight":0.262},{"period":"ytd","weight":0.0336}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京赛升药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"34145人(较上一季度减少0.04%)","perCapita":"8019股","listingDate":"2015-06-26","address":"北京市大兴区北京经济技术开发区兴盛街8号","registeredCapital":"48166万元","survey":" 北京赛升药业股份有限公司的主营业务是注射针剂的研发、生产及销售。公司的主要产品是免疫系统用药、神经系统用药、心脑血管用药。赛盈纤溶酶注射液被评选为2023年年度生化生物企业优秀品牌，赛典单唾液酸四己糖神经节苷脂钠注射液被评为2024年度生化、生物药品优秀品牌。","listedPrice":38.46},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"赛升药业(300485)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供赛升药业(300485)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"赛升药业,300485,赛升药业股票,赛升药业股票老虎,赛升药业股票老虎国际,赛升药业行情,赛升药业股票行情,赛升药业股价,赛升药业股市,赛升药业股票价格,赛升药业股票交易,赛升药业股票购买,赛升药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"赛升药业(300485)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供赛升药业(300485)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}